Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by HASCHEK, W. M.
Right arrow Articles by TOMPKINS, W. A. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by HASCHEK, W. M.
Right arrow Articles by TOMPKINS, W. A. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 Oxford University Press

other

Zidovudine Toxicity to Cats Infected with Feline Leukemia Virus

WANDA M. HASCHEK, RONALD M. WEIGEL, GAIL SCHERBA, MA, CRISTINA DEVERA, RHONDA FEINMEHL, PHILIP SOLTER, MARY B. TOMPKINS1 and WAYNE A. F. TOMPKINS1

Department of Palhobiology, College of Veterinary Medicine, University of Illinois Urbana, Illinois61801

Received July 27, 1989; accepted December 18, 1989

Zidovudine Toxicity to Cats Infected with Feline Leukemia Virus. HASCHEK, W. M., WEIGEL, R. M., SCHERBA, G., DEVERA, M. C, FEINMEHL, R., SOLTER, P., TOMPKJNS, M. B., AND TOMPKINS, W. A. F. (1990). Fundam. Appl. Toxicol. 14, 764–775. Feline leukemia virus (FeLV) infection of cats is a model for the acquired immunodeficiency syndrome in humans. The toxicity of zidovudine was evaluated in SPF cats experimentally infected with FeLV. At initiation of the zidovudine study, all cats were antibody positive for FeLV antigens but clinically asymptomatic. Four cats were also viremic. Thirteen, 6- to 10-month-old cats were divided into five dosage groups and given zidovudine po at 0, 7.5, 15, 30, or 60 mg/kg daily in three equally divided doses for 32 to 34 days. Titers of circulating virus antigen remained constant; however, three of six cats receiving the higher doses of zidovudine (≤30 mg/kg) showed an increase in antibody titers to FeLV. Administration of zidovudine resulted in a progressive anemia, dependent upon dose and time. Macrocytes were observed prior to the development of anemia and were also found in several nonanemic cats. Repeated measures regression analyses indicated that an increased dose of zidovudine was associated with decreased packed cell volume, red blood cell count, and hemoglobin. As determined from the packed cell volume, the analyses indicate that anemia is induced only by the two highest doses of zidovudine. The regression model indicates that daily doses of 60 and 30 mg/kg are expected to induce anemia by Day 4 and Day 13, respectively. Progressive absolute neutropenia was observed in the ≤30 mg/kg groups. Histopathologic lesions consisted of marked bone marrow hypercellularity in cats given ≤30 mg/kg zidovudine and splenic extramedullary hematopoiesis in cats given ≤15 mg/kg. Thus, oral toxicity of zidovudine in the cat is manifested by a dose-related anemia and neutropenia as observed in humans.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.